These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 7581116

  • 1. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality.
    Bacigalupo A, Tedone E, Isaza A, Soracco M, Van Lint MT, Sanna A, Frassoni F, Occhini D, Gualandi F, Lamparelli T.
    Bone Marrow Transplant; 1995 Jul; 16(1):155-61. PubMed ID: 7581116
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S, Zikos P, Van Lint MT, Tedone E, Occhini D, Gualandi F, Lamparelli T, Mordini N, Berisso G, Bregante S, Bruno B, Bacigalupo A.
    Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
    Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Mordini N, Berisso G, Bregante S, Bacigalupo A.
    Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R, Ross S, Hüsing J, Ottinger H, Elmaagacli A, Roggendorf M, Schaefer UW, Runde V.
    Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
    Cartón JA, Maradona JA, de Oña M, Asensi V, Melón S, García-Alcalde ML, Rodríguez-Junquera M, Moreno-Torrico A, de Zárraga M.
    Med Clin (Barc); 1999 Sep 04; 113(6):205-9. PubMed ID: 10472608
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR.
    Biol Blood Marrow Transplant; 2001 Sep 04; 7(11):620-30. PubMed ID: 11760150
    [Abstract] [Full Text] [Related]

  • 11. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality.
    Bacigalupo A, Tedone E, Sanna MA, Moro F, Van Lint MT, Grazi G, Balestreri M, Frassoni F, Occhini D, Gualandi F.
    Haematologica; 1992 Sep 04; 77(6):507-13. PubMed ID: 1337746
    [Abstract] [Full Text] [Related]

  • 12. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.
    Takenaka K, Gondo H, Tanimoto K, Nagafuji K, Fujisaki T, Mizuno S, Miyamoto T, Okamura T, Hayashi S, Eto T, Osaki K, Yamasaki K, Shibuya T, Harada N, Teshima T, Matsuishi E, Minematsu T, Minamishima Y, Harada M, Niho Y.
    Bone Marrow Transplant; 1997 Feb 04; 19(3):241-8. PubMed ID: 9028553
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
    Ksouri H, Eljed H, Greco A, Lakhal A, Torjman L, Abdelkefi A, Ben Othmen T, Ladeb S, Slim A, Zouari B, Abdeladhim A, Ben Hassen A.
    Transpl Infect Dis; 2007 Mar 04; 9(1):16-21. PubMed ID: 17313466
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T, Okamoto S, Matsuoka S, Yajima T, Wakui M, Watanabe R, Ishida A, Iwao Y, Mukai M, Hibi T, Ikeda Y.
    Bone Marrow Transplant; 2000 Apr 04; 25(7):765-9. PubMed ID: 10745263
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin.
    Bacigalupo A, Oneto R, Bruno B, Soracco M, Lamparelli T, Gualandi F, Occhini D, Raiola A, Mordini N, Berisso G, Bregante S, Dini G, Lombardi A, Lint MV, Brand R.
    Bone Marrow Transplant; 1999 Sep 04; 24(6):653-9. PubMed ID: 10490732
    [Abstract] [Full Text] [Related]

  • 20. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2009 Jun 04; 15(6):679-85. PubMed ID: 19450752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.